Author
Listed:
- Ze Rui Wu
(Shanghai Jiao Tong University School of Medicine
First Affiliated Hospital of Wenzhou Medical University)
- Lichong Yan
(Shanghai Jiao Tong University School of Medicine)
- Yan Ting Liu
(Shanghai Jiao Tong University School of Medicine
First Affiliated Hospital of Wenzhou Medical University)
- Lei Cao
(Capital Medical University)
- Yu Hang Guo
(First Affiliated Hospital of Wenzhou Medical University)
- Yong Zhang
(Shanghai Jiao Tong University School of Medicine
First Affiliated Hospital of Wenzhou Medical University)
- Hong Yao
(Shanghai Jiao Tong University School of Medicine)
- Lin Cai
(First Affiliated Hospital of Wenzhou Medical University)
- Han Bing Shang
(Shanghai Jiao Tong University School of Medicine)
- Wei Wei Rui
(Shanghai Jiao Tong University School of Medicine)
- Gang Yang
(The First Affiliated Hospital of Chongqing Medical University)
- Xiao Biao Zhang
(Fudan University)
- Hao Tang
(Shanghai Jiao Tong University School of Medicine)
- Yu Wang
(Shanghai Jiao Tong University School of Medicine)
- Jin Yan Huang
(Shanghai Jiao Tong University School of Medicine)
- Yong Xu Wei
(Shanghai Jiao Tong University School of Medicine)
- Wei Guo Zhao
(Shanghai Jiao Tong University School of Medicine)
- Bing Su
(Shanghai Jiao Tong University School of Medicine)
- Zhe Bao Wu
(Shanghai Jiao Tong University School of Medicine
First Affiliated Hospital of Wenzhou Medical University)
Abstract
Aberrant expression of long noncoding RNA H19 has been associated with tumour progression, but the underlying molecular tumourigenesis mechanisms remain largely unknown. Here, we report that H19 expression is frequently downregulated in human primary pituitary adenomas and is negatively correlated with tumour progression. Consistently, upregulation of H19 expression inhibits pituitary tumour cell proliferation in vitro and tumour growth in vivo. Importantly, we uncover a function of H19, which controls cell/tumour growth through inhibiting function of mTORC1 but not mTORC2. Mechanistically, we show that H19 could block mTORC1-mediated 4E-BP1 phosphorylation without affecting S6K1 activation. At the molecular level, H19 interacted with 4E-BP1 at the TOS motif and competitively inhibited 4E-BP1 binding to Raptor. Finally, we demonstrate that H19 is more effective than cabergoline treatment in the suppression of pituitary tumours. Together, our study uncovered the role of H19-mTOR-4E-BP1 axis in pituitary tumour growth regulation that may be a potential therapeutic target for human pituitary tumours.
Suggested Citation
Ze Rui Wu & Lichong Yan & Yan Ting Liu & Lei Cao & Yu Hang Guo & Yong Zhang & Hong Yao & Lin Cai & Han Bing Shang & Wei Wei Rui & Gang Yang & Xiao Biao Zhang & Hao Tang & Yu Wang & Jin Yan Huang & Yon, 2018.
"Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours,"
Nature Communications, Nature, vol. 9(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-06853-3
DOI: 10.1038/s41467-018-06853-3
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-06853-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.